RayKnowChina Research Map
Shortlist

NanjingNanjing University

Jinling Hospital

东部战区总医院(金陵医院)

Listed for 18 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Jinling Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌9 papers led
  2. Hepatocellular carcinoma肝细胞癌23 papers led1 open trial led
  3. Stomach cancer胃癌20 papers led1 open trial led
  4. Retinoblastoma视网膜母细胞瘤0 papers led
  5. Osteosarcoma骨肉瘤14 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Multiple myeloma多发性骨髓瘤4 papers led1 open trial led
  8. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  9. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  10. IgG4-related diseaseIgG4相关性疾病0 papers led1 open trial led
  11. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  12. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  13. Alport syndromeAlport 综合征5 papers led
  14. IgA nephropathyIgA 肾病10 papers led
  15. Osteogenesis imperfecta成骨不全症0 papers led
  16. Hirschsprung disease先天性巨结肠0 papers led
  17. Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led
  18. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 9 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 0020232024: 1120242025: 222025

5 hospitals in Nanjing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesSurgeryImaging & AIMolecular markers & genomics
Departments in papersGastroenterology / hepatologyRadiation oncology
Papers it led9
  1. Effects of immunoenteric nutrition versus general enteral nutrition on prognosis in patients with squamous cell carcinoma undergoing radical esophagectomy post neoadjuvant chemotherapy.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  2. Predicting Postoperative Recurrence Using a Support Vector Machine for Patients With Esophageal Squamous Cell Carcinoma: Machine Learning Modeling Development and Validation Study.2025JMIR cancerFree full text
  3. Berbamine promotes ferroptosis of esophageal squamous cell carcinoma by facilitating USP51-mediated GPX4 ubiquitination and degradation.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Regulation of IncRNA ZNF667-AS1 in Proliferation and Invasion of Esophageal Squamous Cell Carcinoma Cells via Mediating ceRNA Network.2022Critical reviews in eukaryotic gene expression
  5. A RASSF8-AS1 based exosomal lncRNAs panel used for diagnostic and prognostic biomarkers for esophageal squamous cell carcinoma.2022Thoracic cancerFree full text
  6. Long-term outcomes of robotic-assisted versus thoraco-laparoscopic McKeown esophagectomy for esophageal cancer: a propensity score-matched study.2021Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  7. Development and validation of a new clinical staging system to predict survival for esophageal squamous cell carcinoma patients: Application of the nomogram.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  8. Risk prediction nomogram for major morbidity related to primary resection for esophageal squamous cancer.2021MedicineFree full text
  9. Genetic analysis of rapidly progressing esophageal squamous cell carcinoma: A case report.2021MedicineFree full text
More papers found outside PubMed (not counted)3
  1. 235. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY2024Diseases of the Esophagusarticle
  2. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract
  3. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgeryarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 23 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
23
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 6620232024: 5520242025: 442025

7 hospitals in Nanjing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07769827

    Age 18 years to Not stated (registered criteria)

    Led by Jinling HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging, AI & early detectionRecurrence & prognosis
Departments in papersMedical oncologyRadiology / nuclear medicineGastroenterology / hepatologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led23
  1. Etomidate Improves Antitumor Immunity by Suppressing PD-L1 Expression in Hepatocellular Carcinoma Cells.2026Cellular and molecular gastroenterology and hepatologyFree full text
  2. Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.2025BMC cancerFree full text
  3. Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  4. Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma.2025International journal of immunopathology and pharmacologyFree full text
  5. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.2025The Lancet. OncologyRCT
  6. A novel single-cell model reveals ferroptosis-associated biomarkers for individualized therapy and prognostic prediction in hepatocellular carcinoma.2024BMC biologyFree full text
  7. Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma.2024Biochemical and biophysical research communications
  8. Intraperitoneal PD-1 monoclonal antibody for the treatment of advanced primary liver cancer with malignant ascites: a single-arm, single-center, phase Ib trial.2024ESMO openFree full text
  9. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.2024Frontiers in immunologyFree full text
  10. Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.2024Journal of gastrointestinal cancer
  11. Combination of Peglated-H1/HGFK1 Nanoparticles and TAE in the Treatment of Hepatocellular Carcinoma.2023Applied biochemistry and biotechnologyFree full text
  12. Identification of Key Biomarkers in Hepatocellular Carcinoma Induced by Non-alcoholic steatohepatitis or Metabolic Syndrome via Integrated Bioinformatics Analysis.2023Cellular and molecular biology (Noisy-le-Grand, France)
  13. Insights into the Role of Oxidative Stress in Hepatocellular Carcinoma Development.2023Frontiers in bioscience (Landmark edition)
  14. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  15. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.2023Lancet (London, England)RCT
  16. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.2023Lancet (London, England)RCT
  17. Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis.2022Integrative cancer therapiesFree full text
  18. Radiomics-based MRI for predicting Erythropoietin-producing hepatocellular receptor A2 expression and tumor grade in brain diffuse gliomas.2022Neuroradiology
  19. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer.2021Acta biomaterialia
  20. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.2021Cellular oncology (Dordrecht, Netherlands)Free full text
  21. Mesenchymal stem cell-derived exosomes block malignant behaviors of hepatocellular carcinoma stem cells through a lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis.2021Human cell
  22. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance.2021Human cell
  23. Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer.2021Journal of colloid and interface science
Chinese-language papers (not in the count)2
  1. [Evolution of clinical guidelines for primary liver cancer in China: insights into the development of hepatocellular carcinoma management].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Analysis of the incidence of low viral load/low-level viremia and its associated factors in patients with HBV-related primary liver cancer].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCCRecruitingNCT07769827Lead sponsorN/AStart 2025-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 20 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
20
2021–2025
Trials led
11
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 4420232024: 8820242025: 222025

8 hospitals in Nanjing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07615907

    Age 18 years to 80 years (registered criteria)

    Led by Jinling HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNutrition & recoverySurgeryChemotherapy & combined treatment
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led20
  1. FTO-Mediated m6A Demethylation of CCL2 Promotes Gastric Cancer Progression via Autophagy and Oxidative Stress Regulation.2025Digestive diseases and sciences
  2. LDH and glycolytic activity as predictors of immunotherapy response in gastric cancer: a systematic review and meta-analysis.2025Frontiers in immunologyFree full text
  3. Effect of nutrition-based prehabilitation on the postoperative outcomes of patients with esophagogastric cancer undergoing surgery: A systematic review and meta-analysis.2024Cancer medicineFree full text
  4. The RNA m6A reader IGF2BP3 regulates NFAT1/IRF1 axis-mediated anti-tumor activity in gastric cancer.2024Cell death & diseaseFree full text
  5. Phase angle - A screening tool for malnutrition, sarcopenia, and complications in gastric cancer.2024Clinical nutrition ESPEN
  6. Unraveling the immunogenic cell death pathways in gastric adenocarcinoma: A multi-omics study.2024Environmental toxicology
  7. Impact of body composition, grip strength, and physical performance on clinical outcomes for locally advanced gastric cancer during neoadjuvant chemotherapy: A prospective cohort study.2024Nutrition (Burbank, Los Angeles County, Calif.)
  8. Comparison of bioelectrical impedance analysis and computed tomography for the assessment of muscle mass in patients with gastric cancer.2024Nutrition (Burbank, Los Angeles County, Calif.)
  9. Short-Term Prognostic Effect of Comprehensive Complication Index in Patients With Gastric Cardia Adenocarcinoma.2024The Journal of surgical research
  10. Efficacy of Magnifying Endoscopy with Narrow-Band Imaging in the Diagnosis of Early Gastric Cancer and Gastric Intraepithelial Neoplasia.2024The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  11. Effects of oral immunonutritional supplement on 3-year disease-free survival in gastric cancer patients with pathological stage III after total gastrectomy (CRUCIAL): study protocol of a multicentre, randomised clinical trial.2023BMJ openFree full text
  12. Serum ferritin is associated with sarcopenia and predicts long-term survival for gastric cancer undergoing radical gastrectomy.2023European journal of gastroenterology & hepatology
  13. Long-term survival outcome of locally advanced gastric cancer patients who achieved a pathological complete response to neoadjuvant chemotherapy.2023International journal of clinical oncology
  14. Application of serum gastric function markers and digestive tumor indices to the diagnosis of early gastric cancer and precancerous lesions.2023Saudi medical journalFree full text
  15. The application value of preoperative fat-free mass index within Global Leadership Initiative on Malnutrition-defined malnutrition criteria for postoperative outcomes in patients with esophagogastric cancer.2022Nutrition (Burbank, Los Angeles County, Calif.)
  16. Clinicopathological Significance, Related Molecular Changes and Tumor Immune Response Analysis of the Abnormal SWI/SNF Complex Subunit PBRM1 in Gastric Adenocarcinoma.2022Pathology oncology research : PORFree full text
  17. Survival Response of Patients With Gastric Cancer Treated With Regional Arterial-Perfusion Chemotherapy Is Correlated With Borrmann Classification.2021Anticancer research
  18. Advanced gastric cancer: CT radiomics prediction and early detection of downstaging with neoadjuvant chemotherapy.2021European radiologyFree full text
  19. KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.2021Future oncology (London, England)Free full text
  20. Long-Term Outcome in Gastric Cancer Patients with Different Body Composition Score Assessed via Computed Tomography.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
All its trials on ClinicalTrials.gov, any status13
  1. A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric CancerNot yet recruitingNCT07615907Lead sponsorN/AStart 2026-05
  2. ONS in Gastric Cancer After Total GastrectomyStatus unknownNCT05823272Lead sponsorN/AStart 2024-03
  3. Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric CancerStatus unknownNCT05253716Lead sponsorN/AStart 2022-08
  4. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Lead sponsorN/AStart 2017-06
  5. Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric CancerStatus unknownNCT02949258Lead sponsorPhase 2Start 2017-01
  6. Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer PatientsStatus unknownNCT02338518Lead sponsorPhase 3Start 2015-01
  7. Early Jejunostomy Nutrition Minimizes Time to ChemotherapyStatus unknownNCT01766765Lead sponsorPhase 4Start 2013-04
  8. A Novel Nomogram to Predict the Postoperative Overall Survival in Gastrointestinal Cancer PatientsCompletedNCT05620537Lead (inferred)Start 2022-11
  9. Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical GastrectomyCompletedNCT03238404Lead (inferred)N/AStart 2015-08
  10. ERAS for Patients Received Neoadjuvant ChemotherapyCompletedNCT03272984Lead (inferred)N/AStart 2015-04
  11. Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center StudyCompletedNCT03238820Lead (inferred)N/AStart 2014-01
  12. Development of a Multimodal AI System for GIST ManagementCompletedNCT07454967Study siteStart 2026-03
  13. Multimodal Analgesia in Laparoscopic Radical Gastrectomy With Gastric Cancer: a Multi-center StudyStatus unknownNCT03236051Study siteN/AStart 2017-02

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Nanjing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 14 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 4420232024: 4420242025: 222025

25 hospitals in Nanjing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led14
  1. Inhibition of circ_0127646 Enhanced the Cisplatin Sensitivity in Osteosarcoma Cells via miR-22/KAT6B Axis.2025Journal of biochemical and molecular toxicology
  2. An analysis of extraskeletal osteosarcoma based on the literature.2025Scientific reports
  3. Survival outcomes of patients with brain metastasis of osteosarcoma can be improved by aggressive multi-disciplinary interventions including chemotherapy.2024British journal of neurosurgery
  4. An interactive dose optimizer based on population pharmacokinetic study to guide dosing of methotrexate in Chinese patients with osteosarcoma.2024Cancer chemotherapy and pharmacology
  5. Circular RNA CircSATB2 facilitates osteosarcoma progression through regulating the miR-661/FUS-mediated mRNA of ZNFX1.2024Cellular signalling
  6. FRS2 regulated by miR-429 and miR-206 promotes angiogenesis in osteosarcoma.2024Gene
  7. Identification of RALA as a Therapeutic Target and Prognostic Predictor of Osteosarcoma.2023BioMed research international
  8. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.2023Cell death & disease
  9. Injectable rhein-assisted crosslinked hydrogel for efficient local osteosarcoma chemotherapy.2023International journal of pharmaceutics
  10. A case report of rib osteosarcoma and literature review.2023The clinical respiratory journal
  11. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.2022Computational and mathematical methods in medicine
  12. Circular RNA circFIRRE drives osteosarcoma progression and metastasis through tumorigenic-angiogenic coupling.2022Molecular cancer
  13. Sensitive osteosarcoma diagnosis through five-base telomerase product-triggered CRISPR-Cas12a enhanced rolling circle amplification.2021Analytical methods : advancing methods and applications
  14. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.2021Biochemical and biophysical research communications
Earlier papers (2016–2020)11
  1. MAFB Promotes Cancer Stemness and Tumorigenesis in Osteosarcoma through a Sox9-Mediated Positive Feedback Loop.2020Cancer research
  2. miR-139 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1.2019Frontiers in bioscience (Landmark edition)
  3. The application of 3D-printed titanium mesh in maxillary tumor patients undergoing total maxillectomy.2019Journal of materials science. Materials in medicine
  4. Isoliquiritigenin inhibits the proliferation, apoptosis and migration of osteosarcoma cells.2019Oncology reports
  5. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.2017Cancer letters
  6. SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling.2017DNA and cell biology
  7. Personalized Identification of Differentially Expressed Modules in Osteosarcoma.2017Medical science monitor : international medical journal of experimental and clinical research
  8. Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.2016International journal of biological sciences
  9. Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.2016Orthopaedic surgery
  10. Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma.2016Orthopaedic surgery
  11. MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6.2016Protein & cell
All its trials on ClinicalTrials.gov, any status2
  1. Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)CompletedNCT05277480Study sitePhase 2Start 2022-03
  2. A Study of Endostar Combined With Chemotherapy for Treatment of OsteosarcomaStatus unknownNCT01002092Study sitePhase 2Start 2009-02

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Nanjing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 222025

7 hospitals in Nanjing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
    Phase
    Not given
    Started
    2010-07
    Registry
    NCT04210791

    Age 18 years to 75 years (registered criteria)

    Led by Jinling HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesKidney & bone complicationsDiagnosis, MRD & riskBispecific & antibody drugs
Departments in papersRheumatology & immunology
Papers it led4
  1. The impact of CD81 on immune cells and clinical prognosis in multiple myeloma.2025Annals of hematologyFree full text
  2. Clinicopathological characteristics of light chain proximal tubulopathy: a multicentre case series.2025Journal of clinical pathology
  3. Identification of the CD16low CD56low CD38pos Natural Killer Cell as a Key Subset in Patients with Multiple Myeloma.2022Iranian journal of immunology : IJI
  4. The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients.2021Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
All its trials on ClinicalTrials.gov, any status4
  1. Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for TransplantationStatus unknownNCT06324266Lead sponsorPhase 2/Phase 3Start 2023-04
  2. Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT02248428Lead sponsorPhase 3Start 2012-04
  3. Autologous Stem Cell Transplantation for Patients With AL AmyloidosisEnrolling by invitationNCT04210791Lead (inferred)Start 2010-07
  4. Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.Status unknownNCT02086942Lead (inferred)Phase 2Start 2013-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Nanjing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Nanjing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led no English-language PubMed papers on IgG4-related disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Nanjing for IgG4-related disease46 hospitals in China for IgG4-related disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06285279

    Age 18 years to 65 years (registered criteria)

    Led by Jinling HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney DiseasesRecruitingNCT06285279Lead (inferred)Phase 1Start 2024-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

15 hospitals in Nanjing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Nanjing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 5 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 8.6%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

2 hospitals in Nanjing for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led5
  1. Genetic features and kidney morphological changes in women with X-linked Alport syndrome.2023Journal of medical genetics
  2. Effectiveness of renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis.2023Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  3. Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome.2022Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  4. Establishment of the induced pluripotent stem cell line (NCKDi005-A) from a male patient with Alport syndrome carrying a homozygous frameshift mutation in the COL4A4 gene.2022Stem cell research
  5. Generation of the induced pluripotent stem cell line (NCKDi004-A) from a 17-year-old patient with Alport syndrome carrying a homozygous mutation in COL4A3 gene.2021Stem cell research
Chinese-language papers (not in the count)2
  1. [A case of X-linked Alport syndrome with esophageal leiomyomatosis].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
  2. [Precision diagnosis and therapeutic intervention of Alport syndrome].2024Zhonghua yi xue za zhi
Earlier papers (2016–2020)3
  1. Generation of induced pluripotent stem cell line (NCKDi001-A) from a 19-year-old patient with a novel COL4A5 gene mutation in Alport syndrome.2020Stem cell research
  2. Three Novel Heterozygous COL4A4 Mutations Result in Three Different Collagen Type IV Kidney Disease Phenotypes.2018Cytogenetic and genome research
  3. Novel mutations in COL4A3, COL4A4, and COL4A5 in Chinese patients with Alport Syndrome.2017PloS one
All its trials on ClinicalTrials.gov, any status1
  1. Effects of Dapagliflozin on Progression of Alport SyndromeStatus unknownNCT06226896Lead (inferred)Start 2023-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 10 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.4%.

Papers led
10
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 4420232024: 2220242025: 002025

8 hospitals in Nanjing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led10
  1. The prognostic value of hyperhomocysteinemia in IgA nephropathy.2026International urology and nephrology
  2. Development and External Validation of a Multidimensional Deep Learning Model to Dynamically Predict Kidney Outcomes in IgA Nephropathy.2024Clinical journal of the American Society of Nephrology : CJASN
  3. Advancing the application of the analytical renal pathology system in allograft IgA nephropathy patients.2024Renal failure
  4. Clinicopathological features and long-term prognosis of glomerular diseases associated with mercury-containing cosmetics.2023Journal of nephrology
  5. Clinical characterization of polycythemia vera associated with IgA nephropathy in a single Chinese center: A case series.2023Medicine
  6. Primary Cutaneous Mucormycosis Caused by Rhizopus oryzae in a Pediatric Patient with IgA Nephropathy.2023Mycopathologia
  7. The Spectrum of Biopsy-Proven Kidney Diseases, Causes, and Renal Outcomes in Acute Kidney Injury Patients.2023Nephron
  8. Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy.2022BMC nephrology
  9. Clinical and morphologic spectrum of renal involvement in idiopathic hypereosinophilic syndrome.2021Clinical and experimental nephrology
  10. Use of liquid chromatography-tandem mass spectrometry to perform urinary proteomic analysis of children with IgA nephropathy and Henoch-Schönlein purpura nephritis.2021Journal of proteomics
Chinese-language papers (not in the count)1
  1. [Clinicopathological significance and prognostic value of serum 25-hydroxyvitamin D3 level in children with IgA vasculitis nephritis].2025Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Earlier papers (2016–2020)11
  1. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.2020BMC nephrology
  2. Spectrum and prognosis of renal histopathological lesions in 56 Chinese patients with rheumatoid arthritis with renal involvement.2020Clinical and experimental medicine
  3. Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy.2020EBioMedicine
  4. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.2020Journal of nephrology
  5. Identification of glomerular lesions and intrinsic glomerular cell types in kidney diseases via deep learning.2020The Journal of pathology
  6. [The pathological evaluation of IgA nephropathy].2020Zhonghua yi xue za zhi
  7. Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy.2019American journal of kidney diseases : the official journal of the National Kidney Foundation
  8. [Clinicopathologic features and prognosis of patients with IgA nephropathy superimposed on transplant glomerulopathy].2019Zhonghua yi xue za zhi
  9. Significance of histological crescent formation in patients with IgA vasculitis (Henoch-Schönlein purpura)-related nephritis: a cohort in the adult Chinese population.2018BMC nephrology
  10. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.2017American journal of kidney diseases : the official journal of the National Kidney FoundationRCT
  11. Identification of G8969>A in mitochondrial ATP6 gene that severely compromises ATP synthase function in a patient with IgA nephropathy.2016Scientific reports
All its trials on ClinicalTrials.gov, any status2
  1. The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA NephropathyCompletedNCT01451710Lead (inferred)N/AStart 2011-03
  2. Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA NephropathyCompletedNCT00301600Lead (inferred)N/AStart 2003-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanjing for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Nanjing for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanjing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Nanjing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

东部战区总医院(金陵医院)

Jinling Hospital

南京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Nanjing Jinling Hospital; Affiliated Jinling Hospital; Jingling Hospital; Nanjing General Hospital of Nanjing Military Command; Jinling Hospital (General Hospital of Eastern Theater Command); Cancer Center of Jinling Hospital; Affiliated Jinling Hospital of Nanjing Medical University; Cancer Centre of Jinling Hospital

Suggest a correctionDownload the data